Azotemic renal osteodystrophy; clinical features and bone pathology

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Uremic patients undergoing long-term hemodialysis often experience complications.
• Metabolic bone disease, including osteomalacia and osteitis fibrosa, is common in chronic renal failure.
• Calcification of soft tissues and vasculature is a significant concern.

Purpose of the Study:

• To investigate the long-term effects of hemodialysis on bone metabolism and mineral disturbances.
• To evaluate the impact of dialysate calcium levels on alkaline phosphatase and parathyroid hormone.
• To assess the efficacy of vitamin D analogs in managing renal osteodystrophy.

Main Methods:

• A 10-year observational study involving 543 uremic patients undergoing hemodialysis.
• Monitoring of metabolic calcium disturbances, alkaline phosphatase, and plasma immunoreactive parathyroid hormone (iPTH).
• Analysis of bone histology, including osteomalacic and osteitis fibrosa changes, with and without vitamin D analog administration.

Main Results:

• Hemodialysis was associated with metabolic calcium disturbances, soft tissue calcification, and fractures.
• Elevated alkaline phosphatase was observed with 5.0-6.0 mg/dl dialysate calcium but not with 7.5 mg/dl.
• Long-term hemodialysis led to mixed osteomalacia and osteitis fibrosa, which shifted to predominantly osteomalacia with vitamin D analog treatment.

Conclusions:

• Dialysate calcium levels significantly influence alkaline phosphatase in hemodialysis patients.
• Long-term hemodialysis can induce mixed renal osteodystrophy.
• Vitamin D analogs effectively alter bone histology towards osteomalacia with reduced osteoid thickness.